Abstract
American Journal of HematologyVolume 83, Issue 8 p. 609-610 EditorialFree Access Elevated serum ferritin in patients with a myelodysplastic syndrome: How much of a problem?† Richard Stone, Corresponding Author Richard Stone [email protected] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MADana-Farber Cancer Institute, 44 Binney Street, Boston, MA, 02115Search for more papers by this author Richard Stone, Corresponding Author Richard Stone [email protected] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MADana-Farber Cancer Institute, 44 Binney Street, Boston, MA, 02115Search for more papers by this author First published: 06 June 2008 https://doi.org/10.1002/ajh.21233Citations: 4 † Conflict of Interest: Nothing to report. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Neufield EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions. Blood 2006; 107: 3436– 3441. 2 Cappellini MD,Cohen A,Piga A, et al. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006; 107: 3455– 3462. 3 Vichinsky E,Onyekwere O,Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for treatment of transfusion iron load in sickle cell disease. Br J Haematol 2006; 136: 501– 508. 4 Mahesh S,Ginzburg Y,Verma A. Iron overload in myelodysplastic syndrome. Leuk Lymphoma 2008; 49: 427– 438. Citing Literature Volume83, Issue8August 2008Pages 609-610 ReferencesRelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
